Applied Molecular Transport Inc. (NasdaqCM: AMTI)
Health Care · Biotechnology · US
$—
— today · — 1Y
Applied Molecular Transport Inc. (NasdaqCM: AMTI) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Applied Molecular Transport Inc. across four factors: quality 26/100. Its strongest factor is quality.
AMTI price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -1.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 13
- Next earnings
- —
About Applied Molecular Transport Inc.
Applied Molecular Transport Inc. (AMTI), a biopharmaceutical company in the clinical development phase, was founded in 2010 and is based in South San Francisco, California. The firm is dedicated to discovering and advancing a pipeline of oral and respiratory biologic drug candidates, designed to address a variety of medical conditions including autoimmune, inflammatory, and metabolic diseases. Among its investigational treatments, AMT-101 stands out as the lead candidate. This orally administered, gastrointestinal (GI)-selective biologic, derived from rhIL-10, is presently in Phase II clinical trials for the management of ulcerative colitis and other related inflammatory indications. AMTI is also further developing AMT-126, another oral, GI-selective biologic that harnesses interleukin 22. This compound is currently undergoing Phase I clinical studies for the treatment of disorders stemming from impaired intestinal epithelial barrier function. The company's innovative technology platform allows for the creation and development of a broad spectrum of oral biologic therapeutic approaches, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid (RNA) therapeutics.
- ISIN
- US03824M1099
- Founded
- 2010
- Listed since
- Jun 5, 2020
- Exchange
- Nasdaq Capital Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.79 | +0.48% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $442.24 | -0.36% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.85 | +0.96% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $833.56 | +0.61% |
| argenx SEENXTBR: ARGX | $64.17B | €879.20 | +1.74% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $158.83 | +14.36% |
Figures last refreshed Aug 18, 2026.